CEPHEUS goes live

AstraZeneca Pharmaceuticals, one of the fastest-growing multinationals in South Africa, has launched a landmark national survey of 3 000 patients to quantify the degree of under-treatment of hypercholesterolaemia in this country. A critical study outcome is to understand the psyche of the South African patient on cholesterol-lowering medication; do patients know if they have achieved target cholesterol goals and, more significantly, do they even know their target treatment goals. In an age where according to the South African Heart Foundation, 195 South Africans die every day because of some form of heart disease, these are questions that sorely need answers.